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INTRODUCTION
Subdermal contraceptive implant research and development 
began in 1996 at the Population Council Laboratories in 
New York with the discovery of a biocompatibility of silicone 
in the human body, which later resulted in the development 
of Norplant and Norplant 2 (Jadelle) by the Population 
Council.[1,2] Progestin-releasing subdermal implants are used 
worldwide by many women. It is also increasingly accepted 
as a method of contraception in the less developed countries 
like ours. It is a long-term, efficacious, and easily reversible 
contraceptive with few adverse effects that pose no risk to the 
health of the users.[3,4] Common types of subdermal implants 
include the levonorgestrel-releasing (6 and 2 rods) implants 
both licensed for 5 years and the etonogestrel-releasing single 
rod implant. The women on contraceptive implants do not 
require ongoing effort for long-term and effective use, it is 
independent of coitus, very effective with a reported typical 
use pregnancy rate of 0.05% and fertility returns immediately 
on discontinuation.[5,6]
The modes of action include interference with cervical mucus 
making it thick and difficult for sperm penetration hence 
preventing fertilization,[7,8] prevention of ovulation by altering 
the hypothalamo-pituitary-ovarian axis,[9,10] and may also 
interfere with endometrial development.[10,11] The side effects 
of progestin-releasing contraceptive implants include changes 
in the menstrual pattern (amenorrhea, frequent and prolonged 
menstruation), gastrointestinal difficulties, headaches, acne, 
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breast pain, vaginitis, and weight gain.[6,12] These are mainly 
the complaints of the implant user, and the overall reported 
bleeding or spotting was lower than in the normal menstrual 
period. Complications related to insertion include pain, slight 
bleeding, and hematoma, and breakage that may occur during 
removal. The contraceptive choice project showed that in 
the absence of financial, knowledge, health care provider, or 
logistical barriers, the rate of initiation of long-acting reversible 
contraceptives was higher than any other contraceptive 
method.[13] Subdermal contraceptive implants, especially the 2 
rods levonorgestrel-releasing type is a method that is gaining 
increasing acceptance in the family planning unit of the Federal 
Teaching Hospital, Abakaliki. The status of subdermal implants 
at Abakaliki in terms of knowledge and usage, however, has 
not been evaluated since the inception of the unit. Thus this 
review is aimed at evaluating the use, acceptance, efficacy, and 
complications of subdermal implants in the Federal Teaching 
Hospital, Abakaliki, South-east Nigeria.
MATERIALS AND METHODS
Setting
The family planning unit of the Federal Teaching Hospital, 
Abakaliki in Ebonyi State, Nigeria was established in 2012 
following the merger between Ebonyi State University 
Teaching Hospital and Federal Medical Center both in 
Abakaliki. Prior to the merger, both hospitals were running 
their family planning clinics. The hospital is a tertiary 
institution that also offers secondary care to women within 
Ebonyi and its environs. The family planning clinic obtains 
its clients from the postnatal clinic, the general outpatient 
department, specialist clinics, and referrals from the primary, 
secondary, and private health centers in the state.
Design
This is a retrospective descriptive study that was carried out 
in the family planning clinic of the Federal Teaching Hospital, 
Abakaliki. Data were collected from the records in the family 
planning unit as well as from medical records of users from 
January 1, 2009 to December 31, 2013. Information extracted 
includes age, parity, religion, educational status, marital status, 
occupation, side effects, and the reason for discontinuation. 
The information obtained was recorded and the coded data 
were fed into the computer using Epi Info program (2008) 
of Centers for Disease Control and Prevention Atlanta, 
Georgia, USA version 3.5.1. and analysis was done. Simple 
percentages, Chi-square test, and univariate analysis were 
done and the P < 0.05 was considered significant. Ethical 
approval for the study was obtained from the Hospital Ethical 
Committee.
Sample size calculation
The prevalence of 20% reported for Nigeria from a previous 
study was chosen to calculate the minimum sample size for 
the study as no such studies have been done in Ebonyi State. 
The required sample size was calculated using the following 
formula:
n = Z2 P (1− P)/d2
n = Minimum sample size required
Z =  A number relating to the degree of confidence. For the 
value of confidence of 95%, Z = 1.96
P =  Expected prevalence or proportion from a similar study, 
for Nigeria is 20%
d = The maximum tolerable error for study which is 5%
Thus the estimated minimum sample size was 246, but we 
examined a total of 554 records.
RESULTS
During the study period, a total of 1737 clients were using 
one method of contraception or the other out of which 554 
clients accepted subdermal implants [Table 1]. This gives 
an uptake rate of 31.9%. Acceptance of contraception, 
however, remained low compared to the number of 
deliveries during the period under review [Figure 1]. 
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Figure 1: Yearly acceptance of contraception and subdermal implants
Table 1: Yearly distribution of methods in Federal Teaching 
Hospital, Abakaliki 2009-2013
Methods 2009 2010 2011 2012 2013 Total
Oral contraceptive pills 2 16 12 20 23 73
Injectables 78 46 63 273 290 750
IUCD 50 40 23 52 67 232
Condoms - 2 4 35 63 104
Implants 30 50 40 154 280 554
BTL - 6 - 5 13 24
Total 160 160 142 539 736 1737
IUCD=Intrauterine contraceptive device, BTL=Bilateral tubal ligation
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users accepted 3-keto-desogestrel releasing implant while 
429/554 (77.4%) used the 2 rods levonorgestrel-releasing 
implant.
The mean age in the study was 32.9 (5.2) years, the 
minimum age was 17 years, and maximum age was 
48 years. The majority of the clients, 333/554 (60.1%), 
were aged between 30 and 39 years. Mean parity in the 
study was 4.9 (2.2) and ranged between para 0 and para 
13. The majority of the clients (56.1%) were para 5 and 
above. Five-hundred clients 500/554 (90.3%) had a 
tertiary education (colleges of education, polytechnics, and 
universities) while 469/554 (84.7%) were civil servants, 
535/554 (96.6%) were married while 532/554 (96.0%) 
were Christians [Table 2].
Table 3 shows that 17 clients out of 554 (3.1%) had side 
effects or complications with menstrual disturbances 
(amenorrhea - 58.8%, irregular menstruation - 23.5%, 
prolonged menstruation - 5.9%) as the leading complication. 
Sixty-nine clients (12.5%) discontinued the method with 
the most common reason for discontinuation as desire for 
pregnancy 47/69 (68.1%). About 14.5% (10/69) discontinued 
for unspecified reason, 8/69 (11.6%) discontinued because 
of side effects while 5.8% (4/69) was due for replacement. 
Figure 2 and Table 4 shows parity as the only variable with 
statistically significant relationship with discontinuation 
(P = 0.01, confidence interval = 84.4–90.1%).
DISCUSSION
The acceptance rate of subdermal implants in the study was 
31.9%. This is higher than 20%[14] reported for Nigeria but 
much lower than 93.7% reported in Ilorin.[15] There was no 
new acceptor of the 6 rods levonorgestrel implant during 
the period under review but in a study in Port Harcourt the 
acceptance rate was 5.2%.[16] The reason was because the 
6 rods levonorgestrel implants were not available. About 
22.4% of the clients used 3-keto-desogestrel implant that 
is lower than that reported in Jos with a high continuation 
rate of 98.3%.[17] The reason for this lower implants 
acceptance may be due to the fact that the major acceptors 
of contraception are the educated civil servants while the 
bulk of women of reproductive age in the state were the 
uneducated farmers. The majority of these women have 
poor knowledge of contraception and believe in large family 
size. This problem of poor knowledge and low acceptance 
of methods of contraception has reduced as a result of 
increased community awareness outreaches by the hospital 
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Table 3: Complications or side effects of subdermal implants
Complications n=17 (%)
Amenorrhea 10 (58.8)
Irregular menstruation 4 (23.5)
Prolonged menstruation 1 (5.9)
Weight gain 2 (11.8)
Table 4: Effect of sociodemographic characteristics on 
discontinuation of subdermal implants
Characteristics Usage χ2 P 95% CI
Continued Discontinued
Age (in years)

















House wife 8 0
Marital status








Igwe, et al.: Subdermal implants use in Abakaliki
Journal of Basic and Clinical Reproductive Sciences · January - June 2016 · Vol 5 · Issue 14
and the state government’s Mother and Child Care Initiative. 
This was shown by increased acceptance of family planning 
methods in the last 2 years of the 5 years period reviewed.
The mean age in the study was 32.9 ± 5.2 years. This is similar 
to 32.1 years reported by a study in Jos.[17] The majority of 
the clients (60.1%) were aged between 30 and 39 years. This 
age range of common usage may be due to early marriage 
and completion of family size around this age bracket. The 
mean parity in the study was 4.9 ± 2.2 years. This mean parity 
is higher than the mean parity of 3.6 reported in a study in 
Jos.[17] The majority of the clients were multiparous showing 
that there may be fear of the effects of implants on future 
reproduction among the people. The bulk of the clients were 
married, educated, and Christian civil servants. The educated 
women are more likely to be aware and accept contraception. 
The study was also conducted in a Christian dominated 
South-eastern Nigeria hence the predominance of Christians.
Seventeen clients (3.1%) had side effects or complications in 
the study demonstrating the safety of the method. Menstrual 
disturbance was the most common side effect noted in the 
study. This is similar to the report of a similar study in 
Jos.[17] Sixty-nine clients (12.5%) discontinued the method 
during the 5 year period reviewed and the major reason for 
discontinuation was a desire for pregnancy. The majority of 
the clients, however, used the method for 2 or more years. 
Univariate analysis showed that only parity had statistically 
significant relationship with discontinuation. This correlation 
with parity is understandable as young, married clients 
with low parity and desirous of further pregnancy are more 
likely to discontinue the method. No accidental pregnancy 
(method failure) was recorded during the 5 years reviewed 
demonstrating the efficacy of the method.
The data presented in this study may not be representative 
of the community acceptance rate for subdermal implants. 
Another limitation of the study was poor follow-up and 
documentation of vital information.
A prospective study in the future with proper follow-up, 
documentation, and incorporation of the rural communities 
may overcome these challenges.
CONCLUSION
The subdermal implants contraceptive method is safe and 
efficacious with high acceptance and continuation rates in 
Abakaliki. Intensive health education and awareness rallies 
among the rural populace will improve the acceptance, usage, 
and health of the women.
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